Gapping up
In reaction to strong earnings/guidance: CMGE +5.1%, TSN +3.9%, JD +1.8%
M&A news: BHI +16.1% (Baker Hughes & Halliburton (HAL) to combine in stock and cash transaction valued at $34.6 bln or $78.62/ BHI share), AGN +4.2% (Allergan may be very close to $215/share deal to be acquired by Actavis (ACT), according to reports), PT +4.2% (cont M&A spec), HAS +4.1% (Dreamworks Animation and Hasbro (HAS) M&A talks may be fading, according to reports)
Other news: CADC +53.1% (still checking), ADES +20% (receives positive NASDAQ panel decision; co given until March 27th, 2015 to submit delinquent filings), CLDX +13.6% (announced an interim update from the Phase 2 ReACT study of rindopepimut), FOLD +12.5% (announces positive Phase 3 Data on cardiac and composite endpoints from Fabry Monotherapy Study), SSE +3.3% (Carl Icahn discloses updated portfolio position), OXGN +2.5% (cont momentum pre-mkt), TKMR +1.7% (announces licensing and collaboration agreement with Dicerna (DRNA)), NVAX +1.3% (initiates Phase 2 clinical trial of RSV vaccine in elderly subjects ), TRP +1.2% (Activist may soon send letter to TRP urging company to look at tax strategy, according to reports), ALU +1% (still checking), ESRX +0.8% (Berkshire Hathaway discloses new 449K share stake), PTEN +0.8% (BHI peer)
Analyst comments: MSTX +11.1% (reinstated with a Buy at Canaccord Genuity), PRTO +5.5% (initiated with a Outperform at Robert W. Baird; initiated with a Buy at Stifel), MTG +1.9% (added to Conviction Buy list at Goldman), CSTM +1.6% (upgraded to Outperform from Mkt Perform at Bernstein), THOR +1.4% (upgraded to Outperform from Market Perform at Wells Fargo), VOLC +1.4% (upgraded to Outperform from Neutral at Credit Suisse), BBY +0.7% (target raised to $42 at Stifel)
In reaction to strong earnings/guidance: CMGE +5.1%, TSN +3.9%, JD +1.8%
M&A news: BHI +16.1% (Baker Hughes & Halliburton (HAL) to combine in stock and cash transaction valued at $34.6 bln or $78.62/ BHI share), AGN +4.2% (Allergan may be very close to $215/share deal to be acquired by Actavis (ACT), according to reports), PT +4.2% (cont M&A spec), HAS +4.1% (Dreamworks Animation and Hasbro (HAS) M&A talks may be fading, according to reports)
Other news: CADC +53.1% (still checking), ADES +20% (receives positive NASDAQ panel decision; co given until March 27th, 2015 to submit delinquent filings), CLDX +13.6% (announced an interim update from the Phase 2 ReACT study of rindopepimut), FOLD +12.5% (announces positive Phase 3 Data on cardiac and composite endpoints from Fabry Monotherapy Study), SSE +3.3% (Carl Icahn discloses updated portfolio position), OXGN +2.5% (cont momentum pre-mkt), TKMR +1.7% (announces licensing and collaboration agreement with Dicerna (DRNA)), NVAX +1.3% (initiates Phase 2 clinical trial of RSV vaccine in elderly subjects ), TRP +1.2% (Activist may soon send letter to TRP urging company to look at tax strategy, according to reports), ALU +1% (still checking), ESRX +0.8% (Berkshire Hathaway discloses new 449K share stake), PTEN +0.8% (BHI peer)
Analyst comments: MSTX +11.1% (reinstated with a Buy at Canaccord Genuity), PRTO +5.5% (initiated with a Outperform at Robert W. Baird; initiated with a Buy at Stifel), MTG +1.9% (added to Conviction Buy list at Goldman), CSTM +1.6% (upgraded to Outperform from Mkt Perform at Bernstein), THOR +1.4% (upgraded to Outperform from Market Perform at Wells Fargo), VOLC +1.4% (upgraded to Outperform from Neutral at Credit Suisse), BBY +0.7% (target raised to $42 at Stifel)